If neoadjuvant chemoradiation is employed, follow- up imaging before definitive surgical treatment is necessary. Although the utility of follow-up imaging, particularly FDG-PET/CT, is of debate during and after neoadjuvant therapy to predict response, it does have a critical role in evaluating for the interval development of distant metastases and is commonly used for this purpose. OR aMallinckrodt Institute of Radiology, Saint Louis, Missouri. bUMass Medical School, Worcester, Massachusetts. cPanel Chair, Duke University, Durham, North Carolina. dPanel Chair, University of Alabama Medical Center, Birmingham, Alabama. eThe University of Chicago, Chicago, Illinois; American Society of Clinical Oncology. fEmory University Hospital, Atlanta, Georgia. gHampton VA Medical Center, Hampton, Virginia. hUniversity of California San Francisco, San Francisco, California, Hospitalist. iUniversity of Michigan Health System, Ann Arbor, Michigan. jUniversity of North Carolina Hospital, Chapel Hill, North Carolina; The Society of Thoracic Surgeons. kUniversity of Wisconsin School of Medicine and Public Health, Madison, Wisconsin. lUniversity of Arizona College of Medicine, Phoenix, Arizona. mVanderbilt University Medical Center, Nashville, Tennessee. nNational Institutes of Health, Bethesda, Maryland. oThe University of Texas MD Anderson Cancer Center, Houston, Texas; Commission on Nuclear Medicine and Molecular Imaging. pDavid Grant Medical Center, Travis AFB, California. qSpecialty Chair, Johns Hopkins University School of Medicine, Baltimore, Maryland. rSpecialty Chair, Ohio State University Wexner Medical Center, Columbus, Ohio. The American College of Radiology seeks and encourages collaboration with other organizations on the development of the ACR Appropriateness Criteria through representation of such organizations on expert panels.
Staging and Follow up of Esophageal Cancer. If neoadjuvant chemoradiation is employed, follow- up imaging before definitive surgical treatment is necessary. Although the utility of follow-up imaging, particularly FDG-PET/CT, is of debate during and after neoadjuvant therapy to predict response, it does have a critical role in evaluating for the interval development of distant metastases and is commonly used for this purpose. OR aMallinckrodt Institute of Radiology, Saint Louis, Missouri. bUMass Medical School, Worcester, Massachusetts. cPanel Chair, Duke University, Durham, North Carolina. dPanel Chair, University of Alabama Medical Center, Birmingham, Alabama. eThe University of Chicago, Chicago, Illinois; American Society of Clinical Oncology. fEmory University Hospital, Atlanta, Georgia. gHampton VA Medical Center, Hampton, Virginia. hUniversity of California San Francisco, San Francisco, California, Hospitalist. iUniversity of Michigan Health System, Ann Arbor, Michigan. jUniversity of North Carolina Hospital, Chapel Hill, North Carolina; The Society of Thoracic Surgeons. kUniversity of Wisconsin School of Medicine and Public Health, Madison, Wisconsin. lUniversity of Arizona College of Medicine, Phoenix, Arizona. mVanderbilt University Medical Center, Nashville, Tennessee. nNational Institutes of Health, Bethesda, Maryland. oThe University of Texas MD Anderson Cancer Center, Houston, Texas; Commission on Nuclear Medicine and Molecular Imaging. pDavid Grant Medical Center, Travis AFB, California. qSpecialty Chair, Johns Hopkins University School of Medicine, Baltimore, Maryland. rSpecialty Chair, Ohio State University Wexner Medical Center, Columbus, Ohio. The American College of Radiology seeks and encourages collaboration with other organizations on the development of the ACR Appropriateness Criteria through representation of such organizations on expert panels.